Integrated miRNA-mRNA network analysis identifies miR-182-5p as a potential regulator in COPD pathogenesis.
Saved in:
| Title: | Integrated miRNA-mRNA network analysis identifies miR-182-5p as a potential regulator in COPD pathogenesis. |
|---|---|
| Authors: | Burke H; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom., Ackland J; Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Angermann BR; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Belfield G; Translational Genomics, Centre for Genomics Research, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Cellura D; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom., Etal D; Translational Genomics, Centre for Genomics Research, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Humbert MV; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom., Freeman A; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom., Rydin L; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Ostridge K; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; Early Clinical Development, Respiratory and Immunology R&D Biopharmaceuticals, AstraZeneca, Gothenburg, Sweden., Platt A; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Watson A; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom., Spalluto CM; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom., Staples KJ; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom., Wilkinson TMA; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom. |
| Source: | Frontiers in medicine [Front Med (Lausanne)] 2026 Jun 22; Vol. 13, pp. 1743277. Date of Electronic Publication: 2026 Jun 22 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2296-858X |
|---|---|
| DOI: | 10.3389/fmed.2026.1743277 |
